News & Updates
Filter by Specialty:
Serum ADMA levels linked to circadian BP variability in glaucoma
Serum levels of asymmetric dimethylarginine (ADMA) seem to play a major role in the disturbance of circadian blood pressure (BP) variability in patients with glaucoma, suggests a recent study.
Serum ADMA levels linked to circadian BP variability in glaucoma
27 May 2023Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents
Neither titanium-nitride-oxide (TiNO)–coated stents nor third-generation everolimus-eluting stents (EES) are necessarily better than the other in the treatment of patients with acute coronary syndromes (ACS), with a study showing no significant difference in long-term outcomes following placement of TiNO-coated stents or EES.
Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents
27 May 2023Vitamin D supplementation flops for TB prevention in children
A 3-year course of weekly oral vitamin D supplementation, while safe and effective at increasing serum 25(OH)D concentrations, does little to reduce the risk of contracting tuberculosis (TB) infection in children, as shown in the results of a phase III study.
Vitamin D supplementation flops for TB prevention in children
26 May 2023Brepocitinib doses hold promise in treatment of psoriatic arthritis
Treatment with brepocitinib at 30 and 60 mg daily outperforms placebo at relieving signs and symptoms of psoriatic arthritis (PsA), with a safety profile consistent with that seen in other brepocitinib trials, according to data from a phase IIb study.
Brepocitinib doses hold promise in treatment of psoriatic arthritis
26 May 2023Can fish oil use during pregnancy improve infant outcomes?
Supplementation with fish oil during pregnancy of mothers with overweight or obesity does not appear to have a significant impact on the body composition of infants, reveals a recent study.
Can fish oil use during pregnancy improve infant outcomes?
26 May 2023Which COVID-19 vaccine should SARDs patients on immunomodulators use?
Vaccination with either BNT162b2 or mRNA-1273 results in a comparable risk of breakthrough COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulatory medication, a study has shown.